{"schema_version":"secwatch.filing_event.v1","accession":"0001779128-25-000114","form_type":"8-K","ticker":"SRTA","cik":"0001779128","company_name":"Strata Critical Medical, Inc.","filed_at":"2025-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.962432+00:00","generated_at":"2026-05-17T06:31:02.708656+00:00","sec_items":["1.01","2.01","9.01","3.02","7.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Strata completes $124M acquisition of Keystone Perfusion, updates 2025 guidance","bullets":["Total upfront consideration of $124M (88% cash, 12% stock) at ~9x Keystone's estimated 2025 Adjusted EBITDA of ~$13M.","Up to $23M earn-out payable upon achieving ~25% gross profit growth in each of 2026, 2027, and 2028.","Keystone expected to generate ~$65M revenue and ~$13M Adjusted EBITDA in 2025, with >50% YoY revenue growth.","Updated full-year 2025 guidance: revenue $180-190M, Adjusted EBITDA $13-14M (includes Keystone from Sep 16).","Founder/CEO Louis Verdetto, Michael Hancock, and Christie Campbell remain in current roles post-closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001779128-25-000114","json":"https://secwatch.observer/filing/0001779128-25-000114.json","markdown":"https://secwatch.observer/filing/0001779128-25-000114.md","text":"https://secwatch.observer/filing/0001779128-25-000114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1779128/000177912825000114/0001779128-25-000114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1779128/000177912825000114/srta-20250916.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:31:02.708656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9232710f758fd67b942138aea6f3ba13b3ab8259","claim":"Strata Critical Medical, Inc. completed an acquisition involving Keystone Perfusion Services, LLC, LRV Holdco, Inc. for $124 million, subject to adjustment, payable eighty percent in cash and twenty percent in shares of the Company’s common stock (closed 2025-09-16).","evidence_excerpt":"“Closing”) occurred on September 16, 2025. The aggregate consideration (including contingent consideration) payable by Buyer in connection with the Acquisition consists of (a) $124 million, subject to adjustment as set forth in the Purchase Agreement, payable eighty percent in cash and twenty percent in shares of the Company’s common stock, par value $0.0001 per","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1779128/000177912825000114/0001779128-25-000114-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Keystone Perfusion Services, LLC, LRV Holdco, Inc."},{"label":"Consideration","value":"$124 million, subject to adjustment, payable eighty percent in cash and twenty percent in shares of the Company’s common stock"},{"label":"Closing","value":"2025-09-16"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}